



PATENT
ATTORNEY DOCKET NUMBER: 00398/506001

Certificate of Mailing: Date of Deposit: <u>November 6, 2000</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.	
<u>Michelle Chicos</u>	<u>Michelle P. Chicos</u>
Printed name of person mailing correspondence	Signature of person mailing correspondence

RECEIVED

NOV 16 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Michael E. Mendelsohn

Art Unit: 1646

Serial No.: 09/352,570

Examiner: M. Pak

Filed: July 13, 1999

Title: METHOD FOR ASSAYING COMPOUNDS AFFECTING CELL
DIVISION

Assistant Commissioner of Patents
Washington, D.C. 20231

NOV 15 2000

TECH CENTER 1600/2900

STATEMENT UNDER 37 CFR §§1.821-1.825

Further to the Notice To Comply mailed October 4, 2000, enclosed is an initial sequence listing in accordance with the requirements of 37 CFR §§1.821 through 1.825 and consisting of 5 pages to be inserted at the end of the above-referenced application.

As required by 37 CFR 1.821(c), the sequence listing appears as a separate part of the application. Each sequence in the application appears separately in the sequence listing and each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 CFR §1.821(d), the sequence identifiers are used throughout the

application description and claims to refer to their respective sequences.

As required by 37 CFR 1.821(e), enclosed is a diskette containing a copy of the


sequence listing in computer readable form.

As required by 37 CFR §1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 CFR §1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: Nov. 6, 2000 
Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Application No.: 09/352,570

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE